CurrentmhnPolicy CP.MP.209

Clinical Policy: Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing

Medical necessity criteria and coding guidance for multiplex gastrointestinal pathogen nucleic acid amplification (NAAT) panel testing for patients with suspected infectious gastroenteritis, for use by health plans and providers.

Policy Summary

Payermhn

PolicyClinical Policy: Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing

Policy CodePolicy CP.MP.209

Change TypeNo material change

Effective Date

Next Review Date

Key ActionUse CPT 87505/87506/87507 or 0097U as appropriate and document place-of-service for larger panels; bill 87507 and 0097U only with specified inpatient/ED/observation settings.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

<=5<=5 targets

6-116-11 targets

>11>11 targets

87505/87506/87507/0097UCodes referenced

Medical Necessity and Coverage Criteria

Policy Summary

Payermhn

PolicyClinical Policy: Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing

Policy CodePolicy CP.MP.209

Change TypeNo material change

Effective Date

Next Review Date

Key ActionUse CPT 87505/87506/87507 or 0097U as appropriate and document place-of-service for larger panels; bill 87507 and 0097U only with specified inpatient/ED/observation settings.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Panels up to 5 targets: Gastrointestinal pathogen panel testing of up to five targets is medically necessary when EITHER: A) diarrhea for more than seven days with fever and suspected bacteremia, OR B) suspected enteric fever (typhoid or paratyphoid) in an individual with recent travel to an endemic region or who consumed food prepared by persons with recent endemic exposure.<=5 targets

Panels 6-11 targets: Gastrointestinal pathogen panel testing of up to 11 targets is medically necessary when EITHER: A) diarrhea for more than seven days with fever and suspected bacteremia and the individual is at risk for Clostridium difficile colitis, OR B) persistent diarrhea in immunocompromised individuals.6-11 targets

Panels >11 targets: Gastrointestinal pathogen panel testing of greater than 11 targets is medically necessary for persons who are critically ill or immunocompromised in a healthcare setting (for example, emergency department, inpatient hospital, or observation status).>11 targets

The policy notes important limitations of multiplex nucleic acid amplification testing (NAAT/CIDT) for gastrointestinal pathogens that can affect clinical interpretation. Multipathogen NAATs may detect organisms at nonpathogenic levels and more frequently identify mixed infections, which can obscure the relative clinical importance of each detected pathogen. These assays also require predefined target panels, so negative results do not exclude organisms not included on the panel. Clinicians should interpret positive results in the context of clinical presentation, duration of symptoms, and patient risk factors (for example, immunocompromise), because detection does not always equate to active, clinically relevant infection.

This policy does not use explicit 'not medically necessary' language for broad exclusions, but it does apply place-of-service restrictions for certain large-panel codes. CPT codes 87505 and 87506 (3–5 and 6–11 targets) are described as supporting medical necessity in any place of service, while CPT 87507 and proprietary code 0097U support medical necessity only when billed with specified inpatient/observation/emergency place-of-service codes (see coding tables). Providers must therefore document the appropriate place of service when ordering larger panels to align with the policy's coverage conditions.

Coding and Billing Guidance

CPT codes that support medical necessity in any place of serviceCPTCovered

87505	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets.
87506	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.

CPT / Proprietary codes that support medical necessity with place-of-service restrictionsmixedCovered

87507

Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.

0097U

Gastrointestinal pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 22 targets (Campylobacter [C. jejuni/C. coli/C. upsaliensis], Clostridium difficile [C. difficile] toxin A/B, Plesiomonas shigelloides, Salmonella, Vibrio [V. parahaemolyticus/V. vulnificus/V. cholerae], including specific identification of Vibrio cholerae, Yersinia enterocolitica, Enteroaggregative Escherichia coli [EAEC], Enteropathogenic Escherichia coli [EPEC], Enterotoxigenic Escherichia coli [ETEC] lt/st, Shiga-like toxin-producing Escherichia coli [STEC] stx1/stx2 [including specific identification of the E. coli O157 serogroup within STEC], Shigella/Enteroinvasive Escherichia coli [EIEC], Cryptosporidium, Cyclospora cayetanensis, Entamoeba histolytica, Giardia lamblia, adenovirus F40/41, astrovirus, norovirus GI/GII, rotavirus A, sapovirus].

Place of Service codes supporting medical necessity for larger panelsRevenue

21	Inpatient Hospital
22	Outpatient Hospital (Observation)
23	Emergency Room - Hospital

Provider Actions, Documentation & Billing Rules

Documentation Required

Coding and place-of-service documentation

Use CPT codes 87505, 87506, 87507 and proprietary code 0097U appropriately and document the clinical setting and indication. Smaller panels (87505, 87506) support medical necessity in any place of service when clinical criteria are met. Larger panels (87507, 0097U) only support medical necessity when billed with an appropriate inpatient/observation/emergency place-of-service or when the patient is critically ill or immunocompromised as described in policy. Document the presence of inpatient/ED status or that the patient is critically ill or immunocompromised, and include the clinical rationale (e.g., persistent diarrhea in an immunocompromised individual, suspected enteric fever with relevant travel history, or diarrhea >7 days with fever and suspected bacteremia).

Use 87505 for panels with 3-5 targets; supports medical necessity in any place of service when criteria met.
Use 87506 for panels with 6-11 targets; supports medical necessity in any place of service when criteria met.
Use 87507 (12-25 targets) and 0097U (22 targets) only when billed with an inpatient, observation, or emergency department place of service (see Table 3) or when the patient is critically ill or immunocompromised in a healthcare setting.
Document inpatient/ED/observation place of service on the claim and in the medical record when billing 87507 or 0097U.
Ensure medical record documents specific clinical indication: duration of diarrhea, fever, suspected bacteremia, recent travel for enteric fever risk, immunocompromised status, or critical illness.
Codes listed are supportive of medical necessity per policy but do not guarantee coverage; verify payer billing requirements.

Billing Rule

Panel size vs clinical setting

Larger multiplex panels may not meet medical necessity in outpatient settings unless the patient meets the policy criteria for critically ill or immunocompromised, or the test is ordered during an ED visit, inpatient admission, or observation status. Before ordering and billing larger panels (87507, 0097U), confirm that the encounter setting and clinical documentation meet the policy-defined indications and that place-of-service coding reflects that setting.

Panels >11 targets are medically necessary for critically ill or immunocompromised patients in ED/inpatient/observation only.
If ordering a larger panel for outpatient use, include documentation justifying why a larger panel is clinically necessary and ensure payer acceptance.
Place-of-service must be supported in the medical record to avoid claim denials.

Denial Risk

Place-of-service requirement for larger panels

When billing larger panels, clearly link the chosen CPT/HCPCS code to the documented clinical indication and place of service. Use the listed CPT codes for the corresponding number of targets and document inpatient/ED indications when billing 87507 or 0097U to reduce denial risk.

Select CPT 87505 for 3-5 target panels and 87506 for 6-11 target panels when clinical criteria are met regardless of place of service.
Select CPT 87507 for 12-25 target panels and HCPCS 0097U for 22-target panels only with appropriate place-of-service documentation (inpatient/observation/ED) or qualifying critically ill/immunocompromised status.
Always document the clinical reason (e.g., persistent diarrhea in immunocompromised person, diarrhea >7 days with fever and suspected bacteremia, suspected enteric fever with travel history) in the medical record.

Prior Authorization

Provider actions

Follow payer-specific prior authorization and billing guidance where applicable. Coding inclusion here is informative; check the member's plan for any additional documentation, prior authorization, or billing instructions before submitting claims.

Verify prior authorization requirements with the payer before ordering when indicated by plan rules.
Retain documentation supporting place of service and medical necessity in the medical record in case of audit or appeal.

Definitions

Multiplex NAAT / CIDT — definition of culture-independent diagnostic tests and multiplex NAAT

TermMultiplex NAAT / Culture-Independent Diagnostic Test (CIDT)

DefinitionAssays that qualitatively detect nucleic acid from multiple viral, bacterial, and parasitic pathogens simultaneously from stool specimens for patients with symptoms of gastroenteritis or infectious colitis.

Key capabilitiesSimultaneous detection of multiple targets (viral, parasitic, bacterial) including pathogens previously hard to detect (e.g., norovirus, ETEC, EPEC, EAEC).

Clinical advantagesHigher diagnostic yield and more rapid turnaround than many conventional methods, enabling earlier targeted therapy and infection control measures.

LimitationsRequires predefined target panels, may detect microbes at nonpathogenic levels, and increases detection of mixed infections which can complicate interpretation.

Background

Infectious gastroenteritis commonly presents with diarrhea and vomiting and may be caused by bacterial, viral, or parasitic pathogens. Multiplex NAAT (culture-independent diagnostic testing) detects nucleic acid from multiple viral, bacterial, and parasitic agents simultaneously and generally provides a more rapid and higher-yield identification of pathogens than many conventional methods. This faster turnaround can enable earlier targeted therapy and infection control measures. However, multiplex NAAT may detect nonviable organisms or multiple co-detections, which can complicate interpretation; immunocompromised and critically ill patients are more likely to have severe or prolonged illness and may warrant broader panel testing in acute care settings.